Interim Results from LIQUIK Prospective Study Released at WCLC 2023

News | September 8, 2023

Palo Alto, August 16, 2023 — Lucence announced that interim results for LIQUIK, a prospective international multicenter liquid biopsy study for lung cancer, will be reported at the IASLC 2023 World Conference on Lung Cancer (WCLC) on September 9-12, 2023 [1].

The interim findings presented are based on 120 treatment-naïve metastatic non-squamous non-small cell lung cancer (NSCLC) subjects enrolled in the United States and Singapore. Key objectives are prospective comparisons of Lucence’s LiquidHALLMARK® amplicon-based assay to tissue-based next generation sequencing (NGS), as well as to an FDA-approved circulating tumor DNA (ctDNA) liquid biopsy test.

Key findings from the WCLC interim results include:

  • Concordance of LiquidHALLMARK® ctDNA liquid biopsy with tissue-based profiling across 9 NCCN guideline-recommended biomarkers (G9) — EGFR, ALK, RET, ROS1, NTRK fusions, MET, BRAF, ERBB2 and KRAS — ranged from 93.1% to 100%.
  • In 63 patients with tissue-confirmed G9 biomarkers, LiquidHALLMARK® ctDNA-only testing detected 49 G9 biomarkers as compared to an FDA-approved ctDNA-only liquid biopsy test which detected 42 G9 biomarkers.

“Compelling study data unveils significant achievements of LiquidHALLMARK® in blood-based lung cancer profiling, excelling in the field of liquid biopsy technology and achieving a high degree of concordance with tissue profiling. Its accuracy in detecting tissue-confirmed actionable biomarkers, simply with a blood draw, provides potential for further expansion of precision medicine in metastatic NSCLC.” said Richa Dawar, MD, Assistant Professor of Clinical Medicine at the University of Miami Sylvester Comprehensive Cancer Center and study investigator.

“We are excited about LIQUIK as the world’s first prospective multi-center study of LiquidHALLMARK® liquid biopsy with both tissue and FDA-approved ctDNA-only testing as comparisons.” said Min-Han Tan, MBBS, FRCP, PhD, Founding CEO and Medical Director of Lucence. “Looking forward, I hope that final results encompassing both ctDNA and ctRNA [circulating tumor RNA] testing can help inform the oncology community.”

A 2nd poster presentation will present data on ctRNA amplicon-based sequencing providing an independent and potentially earlier measure of cancer detection versus ctDNA-only profiling, highlighting potential of combined ctDNA-ctRNA technology for early detection of cancer [2].

Poster Presentation Details:

[1] P1.23-03. Dawar R. et al. Amplicon-based liquid biopsy prospectively detects more tissue-confirmed guideline-recommended biomarkers in lung cancer. Session Date & Time: Sunday Sep 10, 2023 5:30 PM – 7:30 PM SGT

[2] P1.13-06. Hum Y. F. et al. Plasma Cell-free RNA Sequencing Enables Sensitive Detection of Lung Cancer. Session Date & Time: Sunday Sep 10, 2023 5:30 PM – 7:30 PM SGT

About Lucence

Lucence is a precision oncology company focused on bringing clarity to cancer care. Our ultrasensitive liquid biopsy tests are based on proprietary AmpliMark™ sequencing technology and data analytics for earlier detection and effective treatment. Lucence operates twin CLIA-licensed, CAP-accredited laboratories in California and Singapore. For more information, visit

About LiquidHALLMARK® ctDNA and ctRNA

LiquidHALLMARK® ctDNA and ctRNA panel combines ctRNA profiling of 36 actionable and emerging fusions with ctDNA profiling of mutations in 80 genes, fusions in 10 genes, and somatic variants in 15 cancer types. LiquidHALLMARK® is powered by AmpliMark, the Company’s proprietary amplicon-based sequencing technology, which uses a unique molecular barcode and error-correction technology to ensure test sensitivity across multiple mutation types for single nucleotide variants and fusion genes.

LiquidHALLMARK® ctDNA and ctRNA will be available mid-September 2023 in Singapore.